GLP-1: Molecular Structure

Molecular Characterization#

GLP-1 is a peptide hormone derived from the proglucagon gene (GCG) through tissue-specific post-translational processing. The biologically active forms are GLP-1(7-36)amide (30 amino acids, C-terminally amidated) and GLP-1(7-37) (31 amino acids, free C-terminal glycine). GLP-1(7-36)amide is the predominant circulating active form, with a molecular weight of 3297.7 Da and the molecular formula C149H225N39O45.

Gene Processing and Biosynthesis#

The proglucagon gene encodes a 160-amino-acid preproglucagon precursor that is differentially processed depending on tissue:

• Pancreatic alpha cells: Prohormone convertase 2 (PC2) produces glucagon, GRPP, IP-1, and the major proglucagon fragment
• Intestinal L-cells: Prohormone convertase 1/3 (PC1/3) produces GLP-1, GLP-2, glicentin, oxyntomodulin, and IP-2

This tissue-specific processing means that the same gene produces the counter-regulatory hormone glucagon in the pancreas and the insulinotropic hormone GLP-1 in the gut — an elegant example of biological economy.

GLP-1(1-36)amide and GLP-1(1-37) are the initial products, but these are biologically inactive. N-terminal truncation by PC1/3 removes six amino acids to produce the active forms GLP-1(7-36)amide and GLP-1(7-37).

Three-Dimensional Structure#

The crystal structure of GLP-1 bound to its receptor (PDB: 3IOL) reveals key structural features:

• Alpha-helical conformation: GLP-1 adopts a continuous alpha-helix from approximately residue 7 through residue 30 when bound to the receptor
• N-terminal flexibility: Residues 7-14 are more flexible in free solution but adopt a structured conformation upon receptor engagement
• Amphipathic character: The helix has a hydrophobic face that contacts the receptor transmembrane domain and a hydrophilic face exposed to solvent

The GLP-1 receptor belongs to the class B (secretin-like) GPCR family and features a large extracellular domain (ECD) that makes initial contact with the C-terminal portion of GLP-1, followed by engagement of the N-terminal region with the transmembrane domain core — the "two-step" binding model.

DPP-4 Degradation#

The extremely short half-life of native GLP-1 (approximately 1-2 minutes) is primarily due to cleavage by dipeptidyl peptidase-4 (DPP-4):

• DPP-4 cleaves the His7-Ala8 bond at the N-terminus
• The resulting GLP-1(9-36)amide is inactive at the GLP-1 receptor
• DPP-4 is expressed on endothelial cells throughout the vasculature and as a soluble form in plasma
• Approximately 50% of newly secreted GLP-1 is degraded before reaching the systemic circulation

This rapid degradation has been the central challenge in developing GLP-1-based therapeutics and has driven two strategies: DPP-4 inhibitors (gliptins) that protect endogenous GLP-1, and DPP-4-resistant GLP-1 receptor agonists.

Structural Basis for Therapeutic Analogs#

Each approved GLP-1 receptor agonist employs different structural strategies to overcome DPP-4 degradation:

Position 8 Modification#

Position 8 (Ala in native GLP-1) is particularly important because it is part of the DPP-4 cleavage site. Substitution with alpha-aminoisobutyric acid (Aib) in semaglutide prevents DPP-4 cleavage while maintaining receptor binding. This single modification is a key contributor to semaglutide's extended half-life.

Acylation Strategy#

Attachment of fatty acid side chains to the peptide backbone enables non-covalent binding to serum albumin, which:

• Protects against enzymatic degradation
• Reduces renal clearance
• Creates an albumin-bound depot that slowly releases active peptide
• Extends the half-life from minutes to hours (liraglutide) or days (semaglutide)

Receptor Binding and Signaling#

GLP-1 receptor activation initiates multiple intracellular signaling cascades:

1. Gs protein coupling: Adenylyl cyclase activation, cAMP production
2. Protein kinase A: Phosphorylation of ion channels and exocytotic machinery
3. Epac2: cAMP-dependent but PKA-independent insulin granule exocytosis
4. Calcium influx: Closure of K-ATP channels, membrane depolarization, calcium entry
5. Beta-arrestin recruitment: Receptor internalization and signal diversification

The glucose-dependent nature of GLP-1's insulinotropic effect arises because many of these signaling steps require basal glucose metabolism in the beta cell to be operative. At low glucose concentrations, the K-ATP channels are already open, and GLP-1 signaling cannot generate sufficient stimulus for insulin release.

Pharmacokinetics of Native GLP-1#

Structure-Activity Relationships#

Key SAR findings for GLP-1 receptor activation:

• His7: Essential for receptor activation; modifications at this position generally reduce potency
• Ala8: DPP-4 cleavage site; substitution with Aib or Gly2 prevents degradation
• Glu9, Phe12, Ile13: Important for helical stability and receptor contact
• Positions 22-30: C-terminal region critical for initial receptor ECD recognition
• C-terminal amidation: Enhances stability and receptor affinity compared to free acid

Related Reading#

• GLP-1 overview and research guide
• Peptides similar to GLP-1
• GLP-1 research evidence